Ontology highlight
ABSTRACT:
SUBMITTER: Nishihori T
PROVIDER: S-EPMC4508238 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature
Nishihori Taiga T Baz Rachid R Shain Kenneth K Kim Jongphil J Ochoa-Bayona Jose L JL Yue Binglin B Sullivan Daniel D Dalton William W Alsina Melissa M
European journal of haematology 20150312 5
We conducted a phase 1/2 trial evaluating the combination of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (CVDD) for newly diagnosed multiple myeloma (MM). The primary objective of the phase 1 was to evaluate the safety and tolerability of maximum planned dose (MPD) and the phase 2 was to assess the overall response rate. Patients received 6-8 cycles of CVDD at four dose levels. There were no dose-limiting toxicities. The MPD was cyclophosphamide 750 mg/m(2) I ...[more]